RESEARCH TRIANGLE PARK, N.C., April 13, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that results of the Company’s Phase I program for ICA-105665, the Company’s lead drug candidate for the treatment of epilepsy and neuropathic pain, will be presented by Greg Rigdon, Ph.D., Vice President, New Product Development, at the Antiepileptic Drug Trials X Conference on Friday, April 17, 2009, at The Biltmore Hotel in Coral Gables, Florida.
